16082736

Source:http://linkedlifedata.com/resource/pubmed/id/16082736

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0034656, umls-concept:C0087111, umls-concept:C0524910, umls-concept:C0681867, umls-concept:C1442989, umls-concept:C1512888, umls-concept:C1881197
pubmed:issue	2
pubmed:dateCreated	2005-8-4
pubmed:abstractText	The aim of this study was to increase virologic response rates by individualized treatment according to the early virologic response.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8503886
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents, http://linkedlifedata.com/resource/pubmed/chemical/Drug Carriers, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2a, http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2a
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	0168-8278
pubmed:author	pubmed-author:DITTO-HCV Study Group, pubmed-author:EliaGianfrancoG, pubmed-author:EstebanJuan IJI, pubmed-author:FerrariCarloC, pubmed-author:GoulisIoannisI, pubmed-author:HansenBettinaB, pubmed-author:HezodeChristopheC, pubmed-author:LaggingMartinM, pubmed-author:LukasiewiczEstherE, pubmed-author:LurieYoavY, pubmed-author:NegroFrancescoF, pubmed-author:NeumannAvidan UAU, pubmed-author:PawlotskyJean-MichelJM, pubmed-author:SchalmSolko WSW, pubmed-author:SoulierAlexandreA, pubmed-author:TalRonenR, pubmed-author:Verheij-HartElkeE, pubmed-author:VrolijkJan-MaartenJM, pubmed-author:ZeuzemStefanS, pubmed-author:von WagnerMichaelM
pubmed:issnType	Print
pubmed:volume	43
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	250-7
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:16082736-Adult, pubmed-meshheading:16082736-Antiviral Agents, pubmed-meshheading:16082736-Dose-Response Relationship, Drug, pubmed-meshheading:16082736-Drug Carriers, pubmed-meshheading:16082736-Drug Therapy, Combination, pubmed-meshheading:16082736-Female, pubmed-meshheading:16082736-Follow-Up Studies, pubmed-meshheading:16082736-Hepacivirus, pubmed-meshheading:16082736-Hepatitis C, Chronic, pubmed-meshheading:16082736-Humans, pubmed-meshheading:16082736-Interferon-alpha, pubmed-meshheading:16082736-International Cooperation, pubmed-meshheading:16082736-Male, pubmed-meshheading:16082736-Middle Aged, pubmed-meshheading:16082736-Polyethylene Glycols, pubmed-meshheading:16082736-RNA, Viral, pubmed-meshheading:16082736-Recombinant Proteins, pubmed-meshheading:16082736-Retrospective Studies, pubmed-meshheading:16082736-Ribavirin, pubmed-meshheading:16082736-Safety, pubmed-meshheading:16082736-Treatment Outcome, pubmed-meshheading:16082736-Viral Load
pubmed:year	2005
pubmed:articleTitle	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
pubmed:affiliation	Saarland University Hospital, Homburg/Saar, Germany. Zeuzem@uniklinik-saarland.de
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III